Related by context. All words. (Click for frequent words.) 71 Hb A1C 70 HbA 1c levels 69 HbA 1c 68 glycosylated hemoglobin HbA1c 68 intact parathyroid hormone 68 A1c levels 68 PASI scores 68 baseline HbA1c 68 serum urate 67 serum uric acid 67 HbA1C levels 66 hemoglobin A1c HbA1c 66 serum PTH 66 elevated creatinine 66 sUA 66 glycated hemoglobin levels 66 hemoglobin A1C 65 serum creatinine levels 65 glycated hemoglobin 65 HOMA IR 65 apolipoprotein B 65 A1C levels 65 serum phosphate 65 serum phosphate levels 65 statistical significance p 65 CVD mortality 65 HbA1c levels 64 blood Phe levels 64 coronary stenosis 64 hsCRP levels 64 NNT = 64 albumin excretion 64 urine albumin 64 AST ALT 64 albumin excretion rate 64 lipid parameters 64 PSA nadir 64 serum calcium 64 HbA1C 64 platelet reactivity 64 MADRS score 63 tHcy 63 ejection fractions 63 hemoglobin A1c levels 63 baseline serum creatinine 63 definite stent thrombosis 63 hydroxyvitamin D levels 63 corticosteroid dose 63 urinary albumin 63 MMSE score 63 Hemoglobin A1c 63 plasma homocysteine 63 iPTH 63 fasting plasma glucose FPG 63 peak VO2 63 serum LDL cholesterol 63 clinically meaningful reductions 63 hsCRP 63 postoperative mortality 63 nmol L. 63 plasma leptin 63 PCWP 63 NIHSS score 63 arterial thromboembolic events 63 concomitant medications 63 BENICAR HCT 63 troponin T 63 NPH insulin 63 carotid stenosis 63 serum ALT 62 serum glucose 62 DAS# scores 62 creatinine ratio 62 nonfasting triglyceride levels 62 mmol l 62 SCr 62 glycated hemoglobin HbA1c 62 serum urate levels 62 ADCS ADL 62 fasting plasma glucose 62 mean baseline HbA1c 62 nmol L 62 atherogenic lipids 62 baseline A1C 62 MoxDuo TM IR 62 serum vitamin D 62 glycemia 62 poor metabolizers 62 CDAI score 62 serum potassium 62 serum concentrations 62 PSADT 62 serum estradiol 62 abdominal adiposity 62 mean serum phosphorus 62 mmHg diastolic 62 density lipoprotein cholesterol 62 left ventricular diastolic 62 serum calcium levels 62 apo B 62 alanine aminotransferase ALT 62 dose Iluvien 62 inflammatory biomarkers 61 cardio respiratory fitness 61 mEq L 61 neutrophil counts 61 hematological adverse 61 PREZISTA r arm 61 Triglyceride levels 61 hemoglobin concentrations 61 glomerular filtration rate 61 serum IGF 61 urinary N telopeptide 61 fasting glucose levels 61 Primary endpoints 61 CPAP adherence 61 mg BID dose 61 ARB telmisartan 61 Crohn Disease Activity 61 KDOQI 61 Scale EDSS score 61 lipid lowering agents 61 Hb A1c 61 tissue oxygenation 61 interrater reliability 61 elevated IOP 61 subclinical hypothyroidism 61 WOMAC pain 61 laboratory abnormalities 61 serum clusterin levels 61 arterial oxygen saturation 61 aspartate aminotransferase AST 61 atherogenic dyslipidemia 61 echocardiographic parameters 61 T2DM 61 attain statistical significance 61 intima media thickness 61 calculated creatinine clearance 61 serum lipid 61 serum BDNF 61 HbA1c 61 serum magnesium 61 IOP lowering 61 μmol L 61 lumbar spine BMD 61 A1c 61 serum triglyceride levels 61 MACCE 61 Cronbach alpha 61 pharmacokinetic PK profile 61 CIMZIA ™ 61 serum testosterone 61 fasting hyperglycemia 61 HRQL 61 diastolic blood pressures 61 apnea hypopnea 61 alanine aminotransferase 61 homocysteine concentrations 61 psychiatric comorbidities 61 certolizumab 61 serum HCV RNA 61 serum parathyroid hormone 60 elevated LDH 60 glycosylated hemoglobin 60 metabolic parameters 60 serum sodium 60 extrapyramidal symptoms 60 CHD mortality 60 periprocedural 60 cTnT levels 60 elevated uric acid 60 SGPT 60 TEAEs 60 serum lipid levels 60 urinary oxalate 60 p = .# [002] 60 gastric pH 60 apnea hypopnea index 60 psychiatric comorbidity 60 lymphocyte count 60 blood Phe 60 glomerular filtration 60 serum bilirubin 60 glycosylated hemoglobin levels 60 serum folate 60 exhaled nitric oxide 60 statistically nonsignificant 60 #OHD 60 cardiac autonomic 60 intracranial hemorrhage ICH 60 transaminase elevations 60 NIHSS 60 thyrotropin levels 60 plasma triglycerides 60 nonfasting triglycerides 60 moderate renal impairment 60 subscore 60 HDL C 60 arterial thickening 60 serum TSH 60 serum homocysteine 60 pulmonary capillary wedge 60 #mg/dL [001] 60 hemoglobin A1c 60 transaminases 60 leukocyte count 60 serum cortisol 60 triacylglycerol concentrations 60 serum cholesterol 60 serum phosphorus 60 pressor response 60 adiponectin levels 60 microvascular complications 60 x ULN 60 HER2 expression 60 angiographic restenosis 60 β blockers 60 transaminase levels 60 elevated ALT 60 diastolic pressures 60 LVEF 60 fluticasone salmeterol 60 hypoglycemic events 60 QTc prolongation 60 symptomatic VTE 60 Kaplan Meier estimates 60 mmol L. 60 triglyceride concentrations 60 sensitivity specificity 60 multivariable analysis 60 posttreatment 60 lipid lowering medications 60 residual platelet reactivity 60 plasma cortisol 60 postprandial glucose 60 SUVmax 60 serum retinol 60 #mmHg [001] 59 thyrotropin 59 colorectal adenoma 59 metabolite concentrations 59 hemoglobin Hb 59 fasting blood glucose 59 depressive symptom 59 fasting glucose 59 Reynolds Risk Score 59 EDSS scores 59 hs CRP 59 serum triglycerides 59 serum aminotransferase levels 59 cTnT 59 ng dL 59 macrovascular events 59 dyslipidaemia 59 pulmonary exacerbations 59 glycemic variability 59 UACR 59 serum folate concentrations 59 CORE OM 59 cystatin C 59 creatinine levels 59 mcg mL 59 urinary cortisol 59 pg ml 59 RBP4 59 SGRQ 59 fasting insulin 59 coronary revascularization procedures 59 Score IPSS 59 ACh 59 blood glucose concentrations 59 microalbuminuria 59 nonfatal MI 59 noncardiovascular mortality 59 prolactin levels 59 HBeAg seroconversion 59 adenoma recurrence 59 preoperative PSA 59 macroalbuminuria 59 mL/min/#.# m 2 59 postoperative complication 59 Serum creatinine 59 binary restenosis 59 cerebral oxygen saturation 59 elevated LDL cholesterol 59 Subgroup analyzes 59 neutropaenia 59 MMSE scores 59 ADCS CGIC 59 CK MB 59 UPDRS scores 59 XIENCE V PROMUS Stent 59 estimated GFR 59 angiotensin converting enzyme inhibitors 59 serum HBV DNA 59 % Confidence Interval 59 urate levels 59 plasma HCV RNA 59 urinary albumin excretion 59 tertiles 59 salivary flow 59 interobserver reliability 59 UPDRS motor 59 morphometric vertebral fractures 59 hip BMD 59 μg L 59 HIV HCV coinfected 59 carotid IMT 59 periprocedural MI 59 aminotransferases 59 CI -#.# 59 intraclass correlation coefficient 59 diastolic BP 59 cholesterol LDL C 59 transferrin saturation 59 inotropic 59 oxycodone CR 59 pharmacodynamic parameters 59 hypomagnesemia 59 comorbid conditions 59 nocturnal hypoglycaemia 59 plasma lipid 59 ALT elevation 59 DAS# remission 59 Secondary efficacy endpoints 59 BPH Symptom Score 59 EDSS score 59 endometrial thickness 59 antibody titer 59 -#.# mg dL [002] 59 cortisol secretion 59 tapentadol ER 58 triglyceride concentration 58 nonvertebral fractures 58 haematologic 58 clinically meaningful improvement 58 sustained virological response 58 myocardial viability 58 highest tertile 58 carotid plaque 58 prospectively defined 58 sociodemographic factors 58 NYHA functional class 58 LDL HDL 58 serum PSA 58 MDRD 58 aminotransferase levels 58 statin monotherapy 58 serum CRP 58 multivariable adjustment 58 antioxidant supplementation 58 fructosamine 58 urinary calcium excretion 58 systolic BP 58 premorbid 58 secondary efficacy endpoint 58 spirometric 58 thyroid stimulating hormone 58 exploratory endpoints 58 paraprotein 58 SGOT 58 tipranavir r 58 serum phosphorous 58 BMI percentiles 58 virologic responses 58 Baseline characteristics 58 advanced adenoma 58 plasma homocysteine levels 58 mIU L 58 hematological toxicity 58 linear pharmacokinetics 58 ACR# response 58 urinary calcium 58 serum ferritin 58 density lipoprotein cholesterol HDL 58 serum sodium levels 58 p = #.# [003] 58 ALT elevations 58 PSA kinetics 58 SpO 2 58 hematologic parameters 58 antihypertensive medications 58 HAM D# scores 58 serum potassium levels 58 nonadherence 58 hematologic toxicity 58 Ejection Fraction 58 ACCORD Lipid 58 serum cotinine 58 orthostatic hypotension 58 lowest tertile 58 OGTT 58 revascularization procedures 58 NIH CPSI 58 NOAEL 58 nicardipine 58 regression coefficients 58 odds ratios ORs 58 tirofiban 58 % CI #.#-#.# [004] 58 N telopeptide 58 confidence intervals CIs 58 thromboembolic 58 salmeterol fluticasone 58 nonsignificant 58 serologically active patients 58 Pharmacokinetic parameters 58 primary aldosteronism 58 liver histology 58 CLBP 58 adrenal function 58 ADAS cog 58 Kaplan Meier curve 58 #.#mmHg 58 covariate 58 prevalences 58 FeNO 58 somatic symptoms 58 pCR 58 NATRECOR R 58 albuminuria 58 baseline FEV 58 Thalomid ® 58 autonomic dysfunction 58 DLQI 58 arterial thromboembolism 58 affective psychoses 58 LDL cholesterol concentrations 58 ATACAND 58 μg liter 58 symptom severity 58 elevated LDL 58 posttest 58 exhaled NO 58 severe exacerbations 58 cardiac troponin T 58 fasting plasma insulin 58 6MWD 58 thyroglobulin 58 NovoLog ® Mix 58 Pearson correlation coefficient 58 visceral adiposity 58 fasting triglycerides 58 mg/m2 dose 58 specific antigen PSA 58 plasma glucose concentration 58 achieved statistical significance 57 urinary excretion 57 β blocker 57 advanced adenomas 57 subscores 57 mean baseline A1C 57 dietary folate 57 arterial elasticity 57 Descriptive statistics 57 treatment emergent AEs 57 RBP4 levels 57 treat NNT 57 mg Proellex 57 D dimer 57 plasma glucose 57 Platelet counts 57 #.#ng/ml 57 logistic regression analyzes 57 APTIVUS r 57 Index CDAI 57 MetS 57 aldosterone antagonist 57 hyperkalemia 57 oral hypoglycemic agent 57 dapagliflozin plus 57 IFN α 57 intraclass correlation coefficients 57 Endothelial dysfunction 57 angiographic outcomes 57 cTnI 57 insula activation 57 glulisine 57 serum albumin 57 A1C 57 left ventricular systolic 57 fasting plasma 57 nonfatal myocardial infarction 57 X ULN 57 intravesical therapy 57 lymphocyte counts 57 anemia hemoglobin 57 airway responsiveness 57 aspartate aminotransferase 57 impaired fasting glucose 57 somatoform disorders 57 intraobserver 57 inhaled glucocorticoids 57 platelet inhibition 57 c reactive protein 57 FTE staffing 57 AUA Symptom Score 57 virological response 57 hepatic enzymes 57 HDL Cholesterol 57 neurocognitive function 57 CR nPR 57 ULORIC 57 depressive symptomatology 57 hyperglycaemia 57 myopathy rhabdomyolysis 57 EXJADE 57 antipsychotic efficacy 57 unmeasured confounding 57 liver transaminases 57 eNO 57 neutrophil count 57 per deciliter mg 57 TNSS 57 Visual Analogue Scale VAS 57 irbesartan 57 salmeterol fluticasone propionate 57 LDL C 57 bezafibrate 57 nanograms milliliter 57 nmol liter 57 cobiprostone 57 adiponectin concentrations 57 hypokalemia 57 Cardiorespiratory fitness 57 serum phosphorus levels 57 oral hypoglycemic agents 57 Montgomery Åsberg Depression 57 CHD CVD 57 eGFR 57 aldosterone antagonists 57 nonfasting 57 evaluable subjects 57 creatinine clearance 57 non menstrual pelvic 57 cardiometabolic risk 57 postintervention 57 8 OHdG 57 nmol l 57 hemoglobin concentration 57 electrophysiologic 57 elevated homocysteine 57 TMP SMX 57 psychosocial variables 57 IRLS score 57 silent myocardial ischemia 57 FOLPI 57 lipid profiles 57 hyperphenylalaninemia HPA due 57 creatine phosphokinase 57 metformin monotherapy 57 lispro 57 vaginal progesterone gel 57 microg 57 dizziness nausea diarrhea 57 CLA supplementation 57 Febrile neutropenia 57 dose cytarabine 57 HAQ DI 57 cystoscopic 57 GnRH agonists 57 Brief Psychiatric 57 atheroma volume 57 -#.# ± [002] 57 serum leptin 57 #mg/dL [002] 57 multivariable adjusted 57 hemoglobin A1C HbA1C 57 #.#mg/dL 57 #ng/ml 57 Lp PLA 2 57 baseline LDH 57 A1Cs 57 BMI z 57 glycaemia 57 hyperhomocysteinemia 57 tertile 57 COPD exacerbations 57 recurrent ischemia 57 lipid elevations 57 hypertensives 57 IGFBP 57 plasma folate 57 systolic dysfunction 57 Medicare Advantage MLR 57 Symptom severity 57 atherothrombotic disease 57 dosage regimens 57 timepoints 57 #.#/#.# mmHg [001] 57 ergocalciferol 57 hematologic adverse 57 μg dL 57 elevated blood glucose 57 umol L 57 nondiabetic patients 57 cerebral oxygenation 57 convergent validity 57 PaO 2 57 PDP MLR 57 cystatin 57 severe hypoglycemic 57 NYHA 57 postdischarge 57 EQ 5D 57 perioperative mortality 57 CONCERTA ® 57 antidiabetic medications 57 etiologic 57 biochemical recurrence 57 oncologic outcomes 57 ng mL 57 LV hypertrophy 57 preoperatively 57 OAB symptoms 57 thrombolytic agents 57 metformin sulfonylurea 57 subclinical atherosclerosis 57 maximally tolerated 57 interobserver 56 steroid dexamethasone 56 antihypertensive drugs 56 DLTs 56 mU L 56 proteinuria 56 Hb levels 56 % CI #.#-#.# [005] 56 HPA axis suppression 56 nonvertebral fracture 56 mineral density 56 obstructive CAD 56 adjuvant systemic 56 NYHA class 56 1c HbA 1c 56 prednisone prednisolone 56 tapentadol IR 56 seroprotection 56 psychopathological symptoms 56 body fatness 56 Adequate vitamin D 56 PON1 enzyme 56 antithrombotics 56 antiplatelet medications 56 -#.# log# 56 androgen depletion 56 infarct size 56 subscale scores 56 NHANES III 56 nitrotyrosine 56 hematological parameters 56 sUA levels 56 mm Hg diastolic 56 serum testosterone levels 56 LV dysfunction 56 tHcy concentrations 56 + PH# 56 IBDQ 56 plasma lipids 56 medication nonadherence 56 microvessel density 56 Fasting blood glucose 56 prognostic indicators 56 pharmacokinetic characteristics 56 oral prednisolone 56 dose atorvastatin 56 chi ^ sup 56 postprandial blood glucose 56 tic severity 56 Capacity FVC 56 symptomatic intracerebral hemorrhage 56 STRIDE PD 56 erythrocyte sedimentation rate 56 hypocalcemia 56 CrCl 56 concomitant AEDs 56 allele frequencies 56 Erythropoietic therapies may 56 prednisone prednisolone plus 56 uncorrected visual acuity 56 postoperative morbidity 56 hypopneas 56 PUFA intake 56 sulphonylurea 56 nondepressed 56 neurocognitive functioning 56 waist girth 56 insulin detemir 56 plasma glucose levels 56 cognitive affective 56 HCV antibody 56 coadministration 56 QTc 56 PANSS scores 56 #/#mmHg 56 Fasting glucose 56 SSRI SNRI 56 dietary calcium intake 56 LDL HDL ratio 56 Score DAS# 56 creatine kinase MB 56 Kaplan Meier analysis 56 correlation coefficients 56 Socioeconomic factors 56 atorvastatin #mg 56 contrast induced nephropathy 56 autoantibody levels 56 prespecified secondary 56 CANCIDAS 56 natriuretic peptides 56 Recurrence Score 56 IBS symptoms 56 systolic blood pressures 56 AGHD 56 hypoglycemic episodes 56 serum creatinine 56 central corneal thickness 56 statistically significant p = 56 CK # plasma concentrations 56 Apidra ® 56 LDL triglycerides 56 troponins 56 elevated triglycerides 56 LS BMD 56 abnormal lipid 56 fasting triglyceride levels 56 isolated systolic hypertension 56 Hyperlipidemia 56 fosamprenavir 56 d dimer 56 noncardiac 56 serum bicarbonate 56 dosing frequency 56 CsA 56 Caloric intake 56 serum lipids 56 elevated CRP 56 corneal thickness 56 HRQOL 56 vaginal pH 56 univariate analyzes 56 hypogonadal 56 oxygen desaturation 56 TC HDL 56 QTc intervals 56 neurodevelopmental outcome 56 #mg dose [002] 56 isoflavone intake 56 undetectable HBV DNA 56 HDRS 56 TNF antagonist 56 TURBT 56 HbF 56 meta regression 56 fibrosis progression 56 pramlintide metreleptin combination 56 histopathologic findings 56 resynchronization therapy 56 SpCO 56 DAS# CRP 56 isoprostane 56 eosinophilia 56 bivariate analysis 56 cardiac perfusion 56 BEXXAR Therapeutic Regimen 56 cytologic 56 creatine kinase 56 hepatic fat 56 cardiorespiratory fitness 56 methotrexate monotherapy 56 reflux symptoms 56 serotonin synthesis 56 sputum eosinophils 56 lipid lowering drugs 56 SELENA SLEDAI 56 magnesium intake 56 hypersomnia 56 O PPDS 56 EDARBI 56 Cortisol levels 56 multivariate regression analysis 56 Insulin sensitivity 56 PC DAC Exendin 56 LDL Cholesterol 56 K DOQI 56 ischemic cardiomyopathy 56 antihypertensive medication 56 serum transaminases 56 nonobese 56 overt nephropathy 56 adrenal suppression 56 dose proportionality 56 achieved ACR# 56 P = .# 56 LDL cholesterol LDL 56 QIDS SR 56 antimuscarinic 56 pegylated IFN 56 TPMT 56 pg mL 56 LDL lowering 56 salivary cortisol 56 protein excretion 56 maximal aerobic capacity 56 desvenlafaxine succinate 56 mg XP# 56 inhaled budesonide 56 oral antidiabetes 56 abdominal circumference 56 antiarrhythmic drug 56 oral anticoagulant therapy 55 hypovolemia 55 interindividual variability 55 Postoperative complications 55 receiving ISENTRESS 55 eosinophil count 55 Apgar scores 55 Viral load 55 log# copies mL 55 sustained virologic response 55 nonresponders 55 pyridostigmine 55 symptomatic intracranial hemorrhage 55 OADs 55 posttransplant 55 NNRTI resistance 55 elevated triglyceride levels 55 FEV ^ sub 55 PlGF 55 Welchol 55 L PPDS 55 YMRS 55 Prehypertension 55 IV bisphosphonates 55 cerebral perfusion 55 secondary efficacy endpoints 55 postoperative AF 55 myeloperoxidase 55 Montgomery Asberg Depression 55 DAS# [002] 55 oral antidiabetic medication 55 antidiabetic medication 55 B7 H3 55 unfavorable cytogenetics 55 #OHD levels 55 PRADAXA 55 lactate dehydrogenase 55 Ishak fibrosis score 55 metabolic acidosis 55 dosing cohort 55 Zevalin consolidation 55 nonpharmacologic 55 recurrent venous thromboembolism 55 FDG uptake 55 arterial stiffness 55 residual confounding 55 tolvaptan 55 retinal thickness 55 chi squared 55 MMSE 55 Skin sterol 55 Adverse effects 55 fragility fracture 55 angiotensin II receptor blockers 55 left ventricular LV 55 Non inferiority 55 hypercholesterolaemia 55 echocardiographic 55 LUTS 55 bad cholesterol LDL 55 cytopenias 55 octreotide LAR 55 improves glycemic 55 overt hypothyroidism 55 myocardial infarction stroke 55 ACEIs 55 internalizing disorders 55 HpSA 55 HRQoL 55 oxcarbazepine 55 femoral neck BMD 55 serum triglyceride 55 mean ± SEM 55 perfusion abnormalities 55 linaclotide treated 55 QTcF 55 teriflunomide 55 atherosclerotic progression 55 death reinfarction 55 mucosal inflammation 55 hepatitis B immunoglobulin 55 neurodevelopmental impairment 55 bacterial prostatitis 55 postprocedure 55 Multivariate analysis 55 Beta coefficient 55 Serum calcium 55 perioperative morbidity 55 cyclic HMB 55 tumor histology 55 Lumbar spine 55 K DOQI guidelines 55 urodynamic parameters 55 MS DRGs 55 UPDRS 55 cranial irradiation 55 hepatic insulin sensitivity 55 impaired endothelial 55 growth hormone secretion 55 Lantus ® 55 antiarrhythmic agents 55 carbohydrate absorption 55 NT proBNP 55 avosentan 55 plasma pharmacokinetics 55 maximally tolerated dose 55 atypical ductal hyperplasia 55 alanine transaminase 55 IIIa inhibitor 55 cerebrovascular events 55 Endothelial function 55 triiodothyronine 55 HSCT 55 virologic breakthrough 55 hemodynamic parameters 55 4mg/kg 55 colorectal neoplasia 55 mIU ml 55 recurrent VTE 55 Fasting plasma glucose 55 hippocampal volume 55 INVEGA ® 55 hydroxy vitamin D 55 predictive validity 55 myocardial ischemia 55 Infusion Reactions Severe 55 pmol L 55 Operative mortality 55 elevated bilirubin 55 acarbose 55 rosuvastatin #mg 55 proton MR spectroscopy 55 symptom exacerbation 55 postoperative pulmonary 55 non hematological toxicities 55 PLMS 55 nephrotoxicity 55 chest radiographs 55 atypical antipsychotic medications 55 receiving Vectibix monotherapy 55 ADHD RS 55 pimecrolimus cream 55 logistic regression model 55 AUA BPH Symptom Score 55 antidiabetic therapy 55 lipid abnormalities 55 6R BH4 55 GH deficiency 55 mmol liter 55 clinico pathological 55 efficacy endpoint 55 LV ejection fraction 55 Complication rates 55 t# c# CLA 55 plasma renin activity 55 amenorrhea 55 aortic regurgitation 55 glucose insulin 55 fractional shortening 55 onset diabetes mellitus 55 lipid levels 55 renal impairment 55 demonstrated clinically meaningful 55 HAMD 55 Unified Parkinson Disease 55 familial AF 55 #.#mmol L [002] 55 HGPIN 55 Elevated triglycerides 55 Myelosuppression 55 serum biomarkers 55 alkaline phosphatase 55 logistic regression models 55 adenoma detection 55 mild renal insufficiency 55 plasma concentrations 55 mixed hyperlipidemia 55 asymptomatic carotid stenosis 55 mm Hg systolic 55 foveal thickness 55 dietary folate intake 55 anion gap 55 FDA defined valvulopathy 55 neonatal morbidity 55 χ 55 hepatic enzyme 55 triacylglycerol 55 viral kinetics 55 macrovascular complications 55 pretest probability